Key Documents

View All Documentation

Transplatin

Name: Transplatin
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

trans-Platinum(II)diammine dichloride, trans-Diamminedichloroplatinum(II), trans-Dichlorodiammineplatinum(II)

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Linear Formula:

Pt(NH₃)₂Cl₂

CAS Number:

14913-33-8

Molecular Weight:

300.05

NACRES:

NA.24

PubChem Substance ID:

329751363

UNSPSC Code:

41116107

MDL number:

MFCD00011623

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

cisplatin

manufacturer/tradename

USP

mp

340 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	BP544	PHR3252	1134357
USP 1672803 Transplatin	BP544 Transplatin	Supelco PHR3252 Transplatin	USP 1134357 Cisplatin
grade pharmaceutical primary standard	grade -	grade certified reference material, pharmaceutical secondary standard	grade pharmaceutical primary standard
manufacturer/tradename USP	manufacturer/tradename BP	manufacturer/tradename -	manufacturer/tradename USP
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical	application(s) pharmaceutical	application(s) pharmaceutical (small molecule)
format neat	format -	format -	format neat
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-30°C	storage temp. -
mp 340 °C (dec.) (lit.)	mp 340 °C (dec.) (lit.)	mp 340 °C (dec.) (lit.)	mp 270 °C (lit.)

Still not finding the right product?

Explore all of our products under Transplatin

pictograms

GHS08,GHS05

signalword

Danger

hcodes

H317,H318,H334

pcodes

P280 - P302 + P352 - P305 + P351 + P338 + P310

Hazard Classifications

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

Storage Class

13 - Non Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

James Chih-Hsin Yang et al.

The Lancet. Oncology, 16(2), 141-151 (2015-01-16)

We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV

Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells.

Wei Qian et al.

Oncotarget, 5(12), 4180-4194 (2014-06-24)

Overcoming platinum drug resistance represents a major clinical challenge in cancer treatment. We discovered a novel drug combination using cisplatin and a class of thioquinazolinone derivatives including mdivi-1 (mitochondrial division inhibitor-1), that induces synergistic apoptosis in platinum resistant tumor cells

Chitosan exerts anticancer activity through induction of apoptosis and cell cycle arrest in oral cancer cells.

Yuniardini S Wimardhani et al.

Journal of oral science, 56(2), 119-126 (2014-06-17)

Chitosan, a multipurpose biomaterial, has been shown to exert effects against several types of cancer including oral cancer. However, the mechanisms underlying the anticancer activities of chitosan on oral squamous cell carcinoma (SCC) cells remain largely unknown. The present study

View All Related Papers

Global Trade Item Number

SKU	GTIN
1672803-25MG	04061833833988

Questions

Reviews

No rating value